Tammy le, MD
Pulmonary Disease · Anaheim, CANPI 1417273830
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by GSK at 31.9% of the total.
Across 406 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Amgen$860
- Mylan Specialty L.p.$770
- Regeneron Healthcare Solutions, Inc.$566
- Sanofi$435
- plus $2K from 27 others
What the payments were for
- Food & beverage$9,29998%
- Education$2092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 149 | $3,029 |
| AstraZeneca | 58 | $1,606 |
| Amgen | 39 | $860 |
| Mylan Specialty L.p. | 33 | $770 |
| Regeneron Healthcare Solutions, Inc. | 19 | $566 |
| Sanofi | 18 | $435 |
| Grifols USA, LLC | 15 | $402 |
| Boehringer Ingelheim | 11 | $281 |
| Verona Pharma, Inc. | 9 | $238 |
| Viatris Specialty LLC | 10 | $225 |
| Bayer | 7 | $212 |
| Baxter Healthcare | 6 | $138 |
| Biohaven Pharmaceuticals, Inc. | 1 | $118 |
| Electromed, Inc. | 5 | $88 |
| Genentech USA, Inc. | 3 | $68 |
| AbbVie(2 entities) | 3 | $56 |
| Insmed, Inc. | 2 | $46 |
| Gilead | 2 | $43 |
| Advanced Respiratory, Inc | 2 | $36 |
| Caris MPI, Inc. | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| United Therapeutics Corporation | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Ambu Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Pfizer | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,508 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 671 | $495,691 |
| OpsumitMacitentan | 24 | $300,825 |
| TezspireTezepelumab-Ekko | 40 | $165,227 |
| AdempasRiociguat | 14 | $157,321 |
| NucalaMepolizumab | 36 | $134,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 179 | $123,706 |
| Dupixent PenDupilumab | 16 | $65,825 |
| Dupixent SyringeDupilumab | 13 | $46,871 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $16,479 |
| Spiriva RespimatTiotropium Bromide | 31 | $15,855 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $14,295 |
| Atrovent HfaIpratropium Bromide | 19 | $12,647 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,270 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 340 | $9,072 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $3,029 | $648,422737 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $28 | $300,82524 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,606 | $291,617231 claims |
| BayerAdempas | $212 | $157,32114 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $281 | $46,62989 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Anaheim
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.